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Abstract
Background: Vulvar cancer is a rare gynaecological cancer. In Burkina Faso, the diagnosis of vulvar cancers is
delayed and the prognosis is poor. However, no specific study on vulvar cancers has been conducted at the
moment. This work aimed to study the characteristics of these cancers.
Methods: This is a prospective study on histologically confirmed primary cancers of the vulva diagnosed between
1st January 2013 and 30th June 2015. The demographic and clinical aspects were studied at the Yalgado
Ouedraogo University Hospital of Ouagadougou (CHU-YO).
Results: We noticed 21 cases of vulvar cancers within 30 months, ranking it as the 4th most common
gynaecological cancer. The average age of the patients was 55 years (standard deviation +/− 6.3) and the median
age was 57 years. Scars resulting from female circumcision, menopause (n = 20) and HIV infection were noticed in
19 cases and 6 cases respectively. The average time from first symptoms to first consultation was 29 months. Pain
and ulceration were the main reasons for consultation. The clinical picture was chiefly an ulcero-granulating
tumour. There was squamous cell carcinoma in 20 cases and basal carcinoma in 1 case. Fifteen patients were at
stage III or IV, where of three patients had metastatic disease. We noticed vitiligo in 9 vulvar cancer cases.
Conclusion: The cancer of the vulva is rare. Women are of menopausal age, are mostly circumcised and
HIV-infection is common. A majority of patients sought consultation at advanced stage of disease, and diagnosis
was belatedly made. Pain and ulceration were the main reasons for consultation. The sensitization of the
population, education for self- examination would allow earlier diagnosis.
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Background
Vulvar cancer is a rare pathology representing 3 to 5 % of
gynaecological cancers [1, 2]. It mainly affects menopausal
and oestrogen-deficient women [2]. The average age of its
occurrence is 60 years [3, 4]. Cases were found in young
women [5, 6]. Buttmann-Schweiger and Baantrup noticed
11.5 and 23 % of vulvar cancers respectively in women
below 50 [5, 7]. Still, its incidence is increasing strongest
in women aged <60 years [6, 8]. Two aetiological forms
are classically described: the dystrophic vulvar cancer in
elderly women (sclerotic lichen) and the cancer developed
on a healthy vulva due to human papilloma virus infection
(HPV) in younger women [9, 10]. Main other risk factors
are HIV infection, and tobacco addiction [11]. Squamous
cell carcinoma is the main histological type [12]. The diag-
nostic stages are different between Europe and Africa with
47.6 % for stage IB in the Netherlands [13] and 45.4 % for
stage III in Nigeria [14]. In Burkina Faso, no specific study
on vulvar cancers has been conducted at the moment.
However, cervical cancer and HPV-infections, one of the
main risk factors of cervical and vulvar cancers are fre-
quent. In addition invasive lesions are not appropriately
managed, because of poverty. The frequency of HPV
lower genital tract infection is 42.1 % in women under
30 and 57.9 % in women over 30 in Ouagadougou (PCR
multiplex) [15]. In Western Africa, other studies
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reported HPV prevalence for women with normal cy-
tology. The highest prevalence of HPV (any type) was
found in Guinea (47.9 %) using PCR technology [16].
In this context which characterizes developing coun-
tries, this work is being carried out to specify demo-
graphic and clinical characteristics of this cancer at the




This was a case-series-study, based on primary cancers of
the vulva at the Yalgado Ouédraogo University Hospital of
Ouagadougou (CHU-YO). It was carried out over the
period from 1st January 2013 to 30th June 2015.
Site of the study
The study took place in Burkina Faso, a country with
limited resources, located in the heart of West Africa.
The data were collected in the departments of General
Surgery, Dermatology-Venereology, and Gynaecology-
Obstetrics of Yalgado Ouédraogo University Hospital of
Ouagadougou (CHU-YO). This Hospital is the most rep-
resentative health care reference center in Burkina Faso.
It is the national reference hospital for the diagnosis and
management of cancers as well. The three above-
mentioned departments together with the laboratory of
anatomy-pathology are the 4 departments involved in
managing cases of vulvar cancers at Yalgado Ouédraogo
University Hospital.
Population of the study
All the patients who were hospitalized at CHU-YO for
vulvar lesions were concerned.
Criteria of inclusion
We included in this study all the patients who were car-
riers of histologically confirmed primary vulvar cancers.
Were excluded cases of secondary vulvar cancers.
Procedures of data collection
The data collection was carried out by giving out a ques-
tionnaire to the patients who were all examined by an
oncologist surgeon, a dermatologist and/or a gynaecolo-
gist. From each patient, sociodemographic data were col-
lected (age, sex, place of residence), vulvar cancer risk
factors (history of genital infections like genital candidia-
sis, trichomoniasis and chlamydia, HIV infection, meno-
pause, tobacco addiction, diabetes, arterial hypertension,
atherosclerosis, sclerotic lichen, pemphigus vulgaris,
lupus, history of personal or family cancers, scar of fe-
male circumcision). The time from first symptoms to
first consultation and the circumstances of admission
were also sought. The physical examination revealed an
elementary lesion and the location and presence of ade-
nopathy. The biopsy and histological examination helped
confirm the diagnosis. The evaluation of the extension was
made thanks to a pulmonary radiography and anabdomino-
pelvic echography, and even better when necessary, a
thoraco-abdominopelvic tomodensitometry examination
was performed.
Analysis of the data
The cancers were classified in accordance with the 2010
WHO TNM and the classification of the International
Federation of Gynaecology and Obstetrics (FIGO).
Results
In 30 months, 2187 cases of cancers were registered in
women. During the same period, 396 cases of gynaeco-
logical cancers were diagnosed. 21 cases involved pri-
mary cancers of the vulva, i.e., 5.3 % of all the
gynaecological cancers. The cancer of the vulva was con-
sidered as the 4th most common diagnosed gynaeco-
logical cancer just after that of the cervix (222 cases),
the uterus (79 cases), and the ovary (74 cases).
The patients’ average age was 55, with range 32–60
years (standard deviation +/− 6.3) (Table 1). The median
age was 57 years. Nineteen patients were circumcised
just from their childhood and were having the scars. All
the wounds resulting from this female circumcision were
traditionally treated by the repeated application of a
strong heat (hot water and /or heated stone). Six pa-
tients were HIV-1 positive, one patient had a coinfection
of HIV-1 and HIV-2 (Table 2). The average time from
first symptoms to first medical consultation was
29 months, ranging from 12 to 60 months (Table 1).
Pain and ulceration were the main reasons for consult-
ation (Table 1). A pronounced symptomatology from
loco-regional expansion of the tumor was the reason for
consultation in 4 cases: There was dysuria (1 case), im-
possibility of sitting down (2 cases), and putrid discharge
(2 cases). The clinical aspect was an ulcero-granulating
tumour (14 cases), an ulcerated tumour (3 cases) and an
ulcero-necrotic tumour (4 cases) (Figs. 1 and 2). The
tumour was coated with a whitish matter in 2 cases. The
localization was clitoral in one case, minor labial in 2
cases, major labial in 8 cases and mixed labial in 5 cases.
The tumour occupied the whole vulva in 5 cases. The
anus was clinically invaded in 3 cases and there was ur-
ethral meatus in 2 cases. A vitiligo located at the level of
the labia and/or of the root of the thighs was present in
9 cases (Figs. 1 and 2). Inguinal adenopathies were
present in 16 cases. They were fixed in 7 cases and fistu-
lated in 3 cases (Fig. 3).
Squamous cell carcinoma was involved in 20 cases and
basocellular carcinoma in 1 case. Three of the patients
had metastases and in 7 cases, the evaluation of the
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extension could not be done. From all 21 patients, 18
women were presented at stages III and IV. Stage I and
stage II of FIGO were noticed in 1 and 2 cases, respect-
ively. The diagnostic stages are summarized in Table 1.
Discussion
In 30 months, we collected 21 cases of primary cancers
of the vulva at CHU-YO. These cancers are actually rare.
They represented 5.3 % of all the gynaecological cancers
diagnosed in the same period (396 cases). In Africa, all
the authors agree that this cancer is rare but its propor-
tion in relation to gynaecological cancers is highly vari-
able, oscillating between 1.3 and 5 % [14, 17, 18]. In our
study, cancer of the vulva was the 4th most common di-
agnosed gynaecological cancer in order of importance
after cancer of the cervix, the uterus, and the ovary. In
the literature, it is either the 4th or 5th gynaecological
cancer [11, 19, 20]. The cancer of the uterus ranks first
in the west European countries [21]. In Africa, it is that
of the cervix [11, 20, 21]. The results from our study are
based clinical observations, and might not be directly
comparable with the ranking of incident cancers from
cancer registries. The type and frequency of the factors
favoring this situation vary from one country to another.
The cancer of the vulva is, classically speaking, a dis-
ease of elderly and menopausal women [1]. The average
age of our patients was 55. In Africa, the average age
varies between 46 and 61 [19, 22, 23]. Some average ages
of 46 and 49 were noticed in Ghana and in Mali [19,
22]. But, in the western European, the average ages are
over 70 [5] and in Overall, 55.7 % of the women were di-
agnosed at the age of 70 years and above [6]. The differ-
ence of the average ages between Europe and the less
developed countries could be explained, by the differ-
ence of life expectancy at birth, which is 59 years in Bur-
kina Faso against 85 years in France [24, 25] but also by
the frequency of HPV infection in Africa [15, 16].
Two aetiological forms of vulvar cancer are classically
described:
– The cancer of menopausal and elderly women
resulting from chronic genital inflammatory
diseases, associated with a mutation of gene P53.
This cancer is frequent in developed countries
where life expectancy is high [5, 6];
– The cancer developed from intra epithelial neoplasia
due to the human papillomavirus infection [9, 10].
Each of our patients had already at least an episode
of genital infection.
HIV infection was noticed in 6 out of 21 patients. The
youngest of whom was 32. This rate is very high com-
pared to the average prevalence rate of HIV infection in
the adult population of Burkina Faso which is 1 % [26].
Table 1 Clinical and histopathological characteristics n = 21
Categories Number
Age (year) ➢ 50 20
<50 1
Median age 57 -
Average age 55 -



































TNM tumor-nodes-metastasis, FIGO international federation of gynecology
and obstetrics
Table 2 Distribution of patients according to risk factors, n = 21
Risk factors Number
HIV 6
History of genital infection 21
Menopause 20
Diabetes 2
High blood pressure 3
Multiple sexual partners (polygamy) 15
Early sex (<19 years) 21
Female circumcision scar 19
Squamous cell carcinoma (front) 1
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The HIV infection, through the resulting immunode-
pression is suspected to predispose to the cancer of the
vulva [10]. The correlation between neoplasia of the low
genital tractus and HIV is so important that the Center
for Disease Control and Prevention has included high-
grade dysplasias and in situ carcinomas as well, in the
classification of HIV, with the invasive cancer of the
cervix considered as a condition defining AIDS. Intra
epithelial neoplasia of the vulva is also more frequent in
HIV-infected women with a relative risk of 29 compared
to the group of HIV-uninfected women [27]. Although
human papillomavirus is strongly suspected to play an
etiologic role in younger women [9, 28, 29], prevalence
could not be confirmed in our series, because of the high
cost of the diagnostic test. However, a previous study in
our country noticed a strong relation between HPV in-
fection and invasive cancers of the cervix [15].
HPV is one of the main risk factor of carcinomas of
the low genital tractus. This led to some hope in the vac-
cines directed against the most frequent genotypes in
Europe (16 and 18) [30]. The newly developed 9-valent
vaccine [31] might be promising in the actual working
context, because HPV genotypes seem to vary from one
country to another, with the predominance of genotypes
52 (29.4 %) and 58 (20.6 %) in Ouagadougou [15]. A part
from the infectious factors, many other risk factors were
reported in the literature. Diabetes, obesity, hyperten-
sion, and atherosclerosis, sclerotic lichen, lupus, pem-
phigus vugaris are suspected to be the factors which are
most frequently associated with vulvar cancers [11, 23].
In addition to these factors, in the researcher’s series,
other factors that could be involved in the appearance of
vulvar cancers were noticed. Nineteen (19/21) of the pa-
tients were having a scar due to female circumcision.
The prevalence of female circumcision in the general
population of those over 50 is not known in Burkina
Faso. However, it is of 76 % among the age group 15–49
years and of 13.3 % in those below 15 [32]. Traditionally,
the scars due to burns are risk factors of cutaneous car-
cinoma (Marjolin’s tumour) [33]. Yet, it has still not
been reported in the literature that female circumcision
can develop vulvar cancers. But the traditional use of
heat repeatedly in order to heal wounds due to female
circumcision could occasion real burns. Thus, the scars
resulting from female circumcision could actually be like
real scars due to burns, risk factors of carcinoma. However,














Fig. 3 1-ulcero-granulating tumor. 2-fixed right inguinal adenopa-






Fig. 1 1 - vitiligo. 2 - tumor
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whether these are independent risk factors or merely coex-
isting medical conditions common to women of this age.
Similarly, the researcher could not come across, in the
literature, cases of cancers of the vulva grown on lesions
of vitiligo. However, this coexistence in almost half of
the patients (9 cases/21), makes the researcher wonder
whether vitiligo is not a risk factor of vulva cancer or
whether both pathologies were not supported by the
same subjacent physiological condition. Besides, though
the relation with vitiligo is not well defined in the litera-
ture, some authors noticed this association. As it is re-
ported in Carii et al., among the patients who presented
an association of sclerotic lichen and vulvar cancer, 16 %
had an antecedent of vitiligo [34].
From a clinical point of view, a mass, a plaque, an
ulcer, a nodule, a genital pruritus, bleedings and post-
menopausal vaginal losses, dyspareunia and inguinal
adenopathies can be occasions for discovery [12]. Pain,
ulceration, and tumefaction were the main reasons for
consultation by our patients.
In the literature, the main localization remains the
major labia. In 10 % of the cases, the lesions are
extremely extensive and the primary site is difficult to
define [9] as it is in 5/21 cases of our patients.
Just as it is in our series, the clinical aspect is chiefly
an ulcero-granulating tumour in the literature [35]. All
the authors agree on the most frequent histological type
which is asquamous cell carcinoma [2, 34]. This is the
case in our study in which there were 20 squamous cell
carcinomas against only one basocellular carcinoma.
The evolution of vulvar cancers has long been locore-
gional, the ganglionary metastasias are premature and
the distant metastasias are late [36]. In our study, only
two patients (2/21) were at stage I or II contrasting with
a small proportion of metastatic cases (3/21). These re-
sults are similar to the data in the African literature in
which the time to first medical consultation was superior
to 6 months in 60 % of the cases and 80 % of the pa-
tients were at stages III and IV of FIGO [14, 19, 37].
This contrasts with stage at diagnosis in the developed
countries. In the USA, 90 % of cases are diagnosed in
situ or at a premature stage of the invasive disease [38].
The diagnoses which are late, in the African environ-
ment might be due to the lack of awareness-raising [11]
and mostly the sociocultural context. Indeed, in our con-
text, the vulva is considered an area of decency and the
patients only come for consultation when there appears
an unbearable sign. This is the case of two of our pa-
tients who came on consultation when they saw a putrid
perineal discharge and when they could not sit down.
Unfortunately, when these signs appear, the tumor is
already at an advanced stage. Let us also note the re-
sponsibility of some health workers who might diagnose
the disease on time, just doing local care. Although there
is no systematic screening for the cancer of the vulva,
patients with history of cervical disease, might benefit
from regular watch over. Likewise, patients with sclerotic
lichens or with history of intraepithelial neoplasia should
be educated to examine themselves through a mirror [2].
Conclusion
The cancer of the vulva is rare. Women are of menopausal
age, are mostly circumcised and HIV-infection is com-
mon. A majority of patients sought consultation at ad-
vanced stage of disease, and diagnosis was belatedly made.
Pain and ulceration were the main reasons for consult-
ation. It was essentially an ulcero-granulating tumour.
The sensitization of the population, education for self-
examination, the treatment of precancerous lesions and
watching over the patients at risk (HIV infection) would
allow earlier diagnosis. Vaccination remains the best way
of prevention, though is it too expensive for a less-
developed country like Burkina Faso.
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